Will Johnson & Johnson's Coronavirus Vaccine Dominate the Market?
Whether from niche vaccine developers or well-established pharmaceutical giants, over 70 potential coronavirus vaccines are currently undergoing development. Johnson & Johnson (NYSE: JNJ) was one of the first companies to declare that it was working on such a vaccine, and in March the company said it anticipates clinical trials beginning this fall.
However, there already being plenty of competition in this area, will Johnson & Johnson's new vaccine have what it takes to stand out against its dozens of rivals? Let's take a look at what the pharmaceutical giant's candidate has going for it right now.
Image source: Getty Images.
Source Fool.com
